In LLC1 tumor-bearing mice, low-dose shIDO-ST treatment preserves T cell populations and monocytes experience an increase in CD86 and MHCII expression indicating that these myeloid cells, similar to neutrophils in the tumor-free model, may have greater ability to present tumor-specific antigen to tolerized T cells. The gene discussed is CD86; the disease is neoplasm.